Chiara Carmen Miceli

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Ferdinando De Vita · 3 shared papers, 2024–2026 · strength 0.65
   • Paper Complete and Persistent Response to Immunotherapy in Highly Pretreated MSS TMB-High Pancreatic Adenocarcinoma: A Case R… DOI 10.3390/ijms27135722↗
   • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
   • Paper Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16040824↗
2. Fortunato Ciardiello · 2 shared papers, 2024–2026 · strength 0.46
   • Paper Complete and Persistent Response to Immunotherapy in Highly Pretreated MSS TMB-High Pancreatic Adenocarcinoma: A Case R… DOI 10.3390/ijms27135722↗
   • Paper Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16040824↗
3. Mario Scartozzi · 1 shared paper, 2026 · strength 0.20
   • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
4. Letizia Procaccio · 1 shared paper, 2026 · strength 0.20
   • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
5. Federico Nichetti · 1 shared paper, 2026 · strength 0.20
   • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
6. Caterina Vivaldi · 1 shared paper, 2026 · strength 0.20
   • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
7. Andrea Pretta · 1 shared paper, 2026 · strength 0.20
   • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
8. Simona Casalino · 1 shared paper, 2026 · strength 0.20
   • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
9. Elisa Giommoni · 1 shared paper, 2026 · strength 0.20
   • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
10. Mariacristina Di Marco · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
11. Sara Lonardi · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
12. Francesca Bergamo · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
13. Guido Giordano · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
14. Matteo Landriscina · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
15. Giuseppe Aprile · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
16. Roberto Bianco · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
17. Monica Niger · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
18. Giampaolo Tortora · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
19. Davide Melisi · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
20. Enrico Vasile · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
21. Alberto Zaniboni · 1 shared paper, 2026 · strength 0.20
    • Paper Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes an… DOI 10.1093/oncolo/oyag085↗
22. Carlo Caputo · 1 shared paper, 2024 · strength 0.16
    • Paper Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16040824↗
23. Alessandro Ottaiano · 1 shared paper, 2024 · strength 0.16
    • Paper Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16040824↗
24. Luca Pompella · 1 shared paper, 2024 · strength 0.16
    • Paper Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16040824↗
25. Donatella Coradduzza · 1 shared paper, 2024 · strength 0.16
    • Paper Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers16040824↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.